# PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

> **NCT06062602** · EARLY_PHASE1 · COMPLETED · sponsor: **Presage Biosciences** · enrollment: 15 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** TAK-676
- **DRUG:** Carboplatin
- **DRUG:** 5-FU
- **DRUG:** Paclitaxel
- **COMBINATION_PRODUCT:** TAK-676 + Carboplatin
- **COMBINATION_PRODUCT:** Carboplatin + Paclitaxel
- **COMBINATION_PRODUCT:** Carboplatin + 5-FU
- **COMBINATION_PRODUCT:** TAK-676 + Carboplatin + 5-FU
- **COMBINATION_PRODUCT:** TAK-676 + Carboplatin + Paclitaxel

## Key facts

- **NCT ID:** NCT06062602
- **Lead sponsor:** Presage Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-26
- **Primary completion:** 2022-11-15
- **Final completion:** 2022-11-15
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06062602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06062602, "PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06062602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*